ANGLE PLC S/ADR - ANPCY STOCK NEWS

ANGLE plc announces significant findings from a study conducted by Edith Cowan University, demonstrating the capability of the Parsortix system to predict immunotherapy responses in small cell lung cancer (SCLC). The study isolated circulating tumor cells (CTCs) from blood samples, identifying PD-L1 expression. In testing 20 samples from 18 patients, CTCs were found in 50%, with 40% showing PD-L1 positivity. This innovative approach provides an alternative to traditional tissue biopsies, potentially enhancing patient selection for immunotherapy, amidst low response rates of 13% to 50% for existing treatments.

ANGLE plc reports groundbreaking findings from researchers at King's College London regarding the role of invasive cellular protrusions in prostate cancer. Their Parsortix system successfully isolated circulating tumor cells (CTCs) in 94% of prostate cancer patients, revealing potential therapeutic targets in the metastatic process. The study highlights how CTCs may form invadopodia for easier bloodstream entry, emphasizing the need for targeted treatments as the survival rate drops significantly once cancer metastasizes. These insights are crucial for developing new therapies aimed at improving patient outcomes.

ANGLE plc has formed a partnership with Solaris Health Holdings and MidLantic Urology to conduct clinical studies on prostate cancer using the Parsortix system. This collaboration aims to evaluate a liquid biopsy as a safer pre-screening tool before invasive biopsies, addressing a significant need in prostate cancer diagnostics. The studies will enroll 100 men with elevated PSA levels, with results expected in 2023. If successful, the Parsortix system could offer a non-invasive option for patients and potentially lead to regulatory submissions, tapping into a vast market with over 11 million annual PSA tests in the U.S.

ANGLE plc (OTCQX: ANPCY) announced a breakthrough in cancer diagnostics with its Parsortix system, isolating circulating tumor cells (CTCs) from both frozen and fresh blood samples with equal efficiency. A study by Fondazione IRCCS Istituto Nazionale dei Tumori showed the system's capability to detect druggable mutations in advanced non-small cell lung cancer (NSCLC) patients. This advancement allows for retrospective analysis and improved sample sharing in multicenter studies. The findings support the potential of tracking mutations in CTCs for better treatment decisions.

ANGLE has achieved a groundbreaking milestone by securing FDA De Novo clearance for its Parsortix system, designed to harvest cancer cells from the blood of metastatic breast cancer patients. This marks the first FDA clearance for a product that extracts intact cancer cells, potentially transforming personalized cancer care. The clearance, earned after over six years of research and extensive clinical testing, positions ANGLE favorably in the growing liquid biopsy market, projected to exceed $100 billion annually in the U.S. alone.

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) announced funding approval from Prostate Cancer UK for a clinical study at Barts Cancer Institute to assess the Parsortix system's effectiveness in predicting prostate cancer progression. The £750,000 grant will support a five-year study involving 200 men facing radical prostatectomy. The trial aims to determine if circulating tumor cells (CTCs) can forecast cancer spread, potentially establishing a new standard of care in prostate cancer treatment. This innovative approach could enhance treatment decision-making, reducing unnecessary surgeries and improving patient outcomes.

ANGLE plc (AIM:AG)(OTCQX:ANPCY) reported preliminary results for the year ending December 31, 2021, highlighting progress on FDA reviews and clinical studies. Revenue increased to £1.0 million, up from £0.8 million in 2020, while losses rose to £15.0 million due to planned investments. Key developments included the launch of clinical laboratories in the UK and US, and completion of patient enrollment in an ovarian cancer study. Cash and equivalents stood at £31.8 million. The company anticipates a regulatory response from the FDA and expects to resume ovarian cancer study analysis soon.

ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a leader in liquid biopsy technology, will release its preliminary results for the year ending December 31, 2021, on April 28, 2022. An analyst meeting is scheduled for 10:00 am BST at Berenberg's London office. A live webcast will be available on ANGLE's Investor Centre page, with a recording accessible later. ANGLE's technology includes the Parsortix system, a liquid biopsy tool designed for comprehensive cancer analysis, and has received a CE Mark in Europe, with an FDA submission underway for use in metastatic breast cancer patients.

ANGLE plc presented results from its Parsortix system at the AACR 2022 conference, showcasing its effectiveness in analyzing circulating tumor cells (CTCs) from triple negative breast cancer (TNBC) patients. The poster highlighted a higher positivity rate for CTCs compared to alternative methods, particularly noting the presence of mesenchymal phenotype CTCs and clusters. This technology supports longitudinal monitoring in cancer drug trials and is part of ANGLE's pharma services. The Parsortix system is designed for non-invasive cancer analysis and has a strong patent portfolio in multiple countries.